Drugs / CC-90009
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04336982 | Aug 2020 → Oct 2023 | acute myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04297124 | Mar 2020 → Jun 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02848001 | Nov 2016 → Apr 2023 | acute myeloid leukemia, myelodysplastic syndrome | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-90009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04297124 ↗ |
| Modality | Other / unclassified | “first-in-class GSPT1-selective cereblon E3 ligase modulator, CC-90009” PMID 33197925 ↗ Feb 2021 |
| Route | Intravenous | “Will be administered intravenously per dosing schedule in a 28-day cycle” NCT02848001 ↗ |
| Target | GSPT1 | “selectively target GSPT1 for ubiquitination and proteasomal degradation” PMID 33197925 ↗ Feb 2021 |